# BPC-157 TB-500 References: The Cited Record Behind the Wolverine Blend

> The full reference list behind this BPC-157 TB-500 digest — peer-reviewed single-compound studies on BPC-157 and Thymosin Beta-4, plus the FDA 503A compounding sources, with DOIs and PubMed links.

Peer-reviewed single-compound studies and the FDA regulatory sources, listed with DOIs and PubMed links.

## Full reference list

Every quantitative and regulatory claim in this BPC-157 TB-500 digest resolves to one of the references below. Citations 1-8 are the peer-reviewed single-compound literature on BPC-157 and Thymosin Beta-4 / TB-500; citations 9-11 are the U.S. Food and Drug Administration sources behind the [Wolverine legal status](/legal-status) and FDA 503A compounding facts. The blend itself has no controlled trial to cite — that absence is the central finding of this record.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies; 35 preclinical, 1 human; no clinical safety data; no TB-500 or combination mention.) https://pubmed.ncbi.nlm.nih.gov/40756949/
[7] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157 and for “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”; effective with the September 29, 2023 update.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[10] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A bulks-list and nomination framework.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[11] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Calendar listing BPC-157, KPV, TB-500, and MOTs-C as substances “being considered for inclusion on the 503A Bulks List.” A scheduled discussion, not a decision.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A barely-there evidence ledger of the BPC-157 and TB-500 record — the few single-compound findings that hold set in one tier, the blend-level and access gaps left one tier down and in plain sight, with no clinic behind the page and nothing here dispensed.